期刊
JOURNAL OF THORACIC ONCOLOGY
卷 16, 期 8, 页码 1321-1332出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2021.04.015
关键词
KRAS; G12C; Sotorasib (AMG 510); Adagrasib (MRTX 849); Secondary mutations
资金
- Japan Society for Promotion of Science [19K16785, 18K07336, 20H03773]
- Boehringer Ingelheim
- Grants-in-Aid for Scientific Research [20H03773, 19K16785, 18K07336] Funding Source: KAKEN
The study developed in vitro models of KRAS G12C cancer resistant to sotorasib and adagrasib, and found that most clones harbored secondary KRAS mutations which showed differential sensitivity to the inhibitors. Sequential use of sotorasib and adagrasib may be considered in some cases, while a combination of BI-3406 and trametinib could be an effective strategy to overcome resistance caused by secondary Y96D and Y96S mutations.
Introduction: KRAS mutations have been recognized as undruggable for many years. Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being developed in clinical trials and have revealed promising results in metastatic NSCLC. Nevertheless, it is strongly anticipated that acquired resistance will limit their clinical use. In this study, we developed in vitro models of the KRAS G12C cancer, derived from resistant clones against sotorasib and adagrasib, and searched for secondary KRAS mutations as on-target resistance mechanisms to develop possible strategies to overcome such resistance. Methods: We chronically exposed Ba/F3 cells transduced with KRASG12C to sotorasib or adagrasib in the presence of N-ethyl-N-nitrosourea and searched for secondary KRAS mutations. Strategies to overcome resistance were also investigated. Results: We generated 142 Ba/F3 clones resistant to either sotorasib or adagrasib, of which 124 (87%) harbored secondary KRAS mutations. There were 12 different secondary KRAS mutations. Y96D and Y96S were resistant to both inhibitors. A combination of novel SOS1 inhibitor, BI-3406, and trametinib had potent activity against this resistance. Although G13D, R68M, A59S and A59T, which were highly resistant to sotorasib, remained sensitive to adagrasib, Q99L was resistant to adagrasib but sensitive to sotorasib. Conclusions: We identified many secondary KRAS mutations causing resistance to sotorasib, adagrasib, or both, in vitro. The differential activities of these two inhibitors depending on the secondary mutations suggest sequential use in some cases. In addition, switching to BI-3406 plus trametinib might be a useful strategy to overcome acquired resistance owing to the secondary Y96D and Y96S mutations. (C) 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据